- Home
- ACV vs GOSS Comparison
ACV vs GOSS Comparison
Compare ACV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- GOSS
- Stock Information
- Founded
- ACV 2015
- GOSS 2015
- Country
- ACV United States
- GOSS United States
- Employees
- ACV N/A
- GOSS N/A
- Industry
- ACV Finance/Investors Services
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ACV Finance
- GOSS Health Care
- Exchange
- ACV Nasdaq
- GOSS Nasdaq
- Market Cap
- ACV 197.6M
- GOSS 203.3M
- IPO Year
- ACV N/A
- GOSS 2019
- Fundamental
- Price
- ACV $21.16
- GOSS $1.11
- Analyst Decision
- ACV
- GOSS Strong Buy
- Analyst Count
- ACV 0
- GOSS 4
- Target Price
- ACV N/A
- GOSS $7.50
- AVG Volume (30 Days)
- ACV 38.8K
- GOSS 1.5M
- Earning Date
- ACV 01-01-0001
- GOSS 05-20-2025
- Dividend Yield
- ACV 9.20%
- GOSS N/A
- EPS Growth
- ACV N/A
- GOSS N/A
- EPS
- ACV N/A
- GOSS N/A
- Revenue
- ACV N/A
- GOSS $114,701,000.00
- Revenue This Year
- ACV N/A
- GOSS N/A
- Revenue Next Year
- ACV N/A
- GOSS $172.31
- P/E Ratio
- ACV N/A
- GOSS N/A
- Revenue Growth
- ACV N/A
- GOSS N/A
- 52 Week Low
- ACV $16.82
- GOSS $0.50
- 52 Week High
- ACV $23.74
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- ACV 65.77
- GOSS 55.81
- Support Level
- ACV $20.25
- GOSS $1.06
- Resistance Level
- ACV $20.58
- GOSS $1.26
- Average True Range (ATR)
- ACV 0.38
- GOSS 0.11
- MACD
- ACV 0.19
- GOSS 0.03
- Stochastic Oscillator
- ACV 89.79
- GOSS 67.95
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.